

microRNA-based cancer cell reprogramming technology (Review)

SHIMPEI NISHIKAWA^{1,2}, HIDESHI ISHII¹, NAOTSUGU HARAGUCHI¹, YOSHIHIRO KANO^{1,2},
TAKAHITO FUKUSUMI^{1,2}, KATSUYA OHTA^{1,2}, MIYUKI OZAKI^{1,2}, DYAH LAKSMI DEWI^{1,2}, DAISUKE SAKAI¹,
TAROH SATOH¹, HIROAKI NAGANO², YUICHIRO DOKI² and MASAKI MORI²

Departments of ¹Frontier Science for Cancer and Chemotherapy and ²Gastroenterological Surgery,
Osaka University, Graduate School of Medicine, Suita, Osaka 565-0871, Japan

Received October 25, 2011; Accepted March 5, 2012

DOI: 10.3892/etm.2012.558

Abstract. Epigenetic modifications play crucial roles in cancer initiation and development. Complete reprogramming can be achieved through the introduction of defined biological factors such as Oct4, Sox2, Klf4, and cMyc into mouse and human fibroblasts. Introduction of these transcription factors resulted in the modification of malignant phenotype behavior. Recent studies have shown that human and mouse somatic cells can be reprogrammed to become induced pluripotent stem cells using forced expression of microRNAs, which completely eliminates the need for ectopic protein expression. Considering the usefulness of RNA molecules, microRNA-based reprogramming technology may have future applications in regenerative and cancer medicine.

Contents

1. Introduction
2. Complete reprogramming
3. Reprogramming-like phenomenon in cancer cells
4. Investigation of other factors
5. Perspectives

1. Introduction

MicroRNAs (miRNAs) modulate mRNA expression through base pairing between seed sequences in miRNA and complementary sequences within the open reading frame or an untranslated region of the target mRNA, thereby destabilizing mRNA and/or inhibiting protein synthesis (1,2). miRNAs play

crucial roles in developmental biology (3,4), stress response (5,6), stem cell physiology (3,4,7), and diseases such as cancer (8-12).

2. Complete reprogramming

Introduction of the transcription factor MyoD into a muscle lineage caused differentiated cells to become myoblasts (13), indicating that single defined biological factors can successfully execute reprogramming of differentiated cells. Three cDNAs, including MyoD, were identified by screening a myocyte cDNA library with proliferating myoblast-specific subtracted cDNA probes. The MyoD cDNA contained a short protein segment similar to an amino acid sequence present in the myc protein family. MyoD cDNA was then transfected into fibroblasts, where it is not normally expressed (mouse C3H10T1/2, NIH3T3, Swiss 3T3, and L cells), and this was sufficient to convert these cells into stable myoblasts. Furthermore, myogenesis occurs to a lesser extent when MyoD is expressed in other lineage-committed adipoblasts.

The hypothesis that one or few transcription factors are sufficient for lineage conversion of terminally differentiated cells is supported by a study showing that C/EBP overexpression can lead to a stepwise reprogramming of B cells, thereby causing them to become macrophages (14). Initial C/EBP expression in B cells inhibits the B-cell commitment transcription factor Pax5, leading to downregulation of its target CD19. This increases the activity of PU.1, an ETS family transcription factor, which results in the upregulation of its target gene Mac-1 and other myeloid markers. This ultimately leads to the conversion of B cells to macrophages (15). Furthermore, three transcription factors, *Ngn3* (also known as *Neurog3*), *Pdx1*, and *Mafa*, are capable of reprogramming differentiated pancreatic exocrine cells in adult mice into cells that closely resemble β -cells. These and several other studies (16,17) clearly indicate that defined biological factors are sufficient for complete lineage conversion of differentiated cells. Lineage conversion, i.e., direct cell reprogramming without reversion to a pluripotent stem cell (PSC) state, is indeed a major step, but the main aim of reprogramming studies is the successful generation of PSCs from differentiated cells. Understanding the mechanism responsible for the successful conversion of adult cells into other cell types would be beneficial for tissue repair, regeneration, and cancer therapy.

Correspondence to: Dr Masaki Mori, Departments of Frontier Science for Cancer and Chemotherapy and Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan
E-mail: mmori@gesurg.med.osaka-u.ac.jp

Key words: miRNA, cancer, stem cell, reprogramming

Takahashi and Yamanaka reported that complete reprogramming can be achieved by the introduction of defined biological factors such as Oct4 (also known as Pou5f1), Sox2, Klf4, and cMyc into mouse (18) and human fibroblasts (19,20). This is a major breakthrough considering the ethical issues related to the use of fertilized oocytes for the establishment and production of embryonic stem (ES) cells and the immunological incompatibility that occurs when unrelated individuals act as donor sources.

3. Reprogramming-like phenomenon in cancer cells

Genetic and epigenetic modifications are the hallmarks of cancer (21), but their roles in the determination of biological behavior have not been completely elucidated (22,23). Considering that cancer initiation and development is based on genetic information, the uncontrolled behavior of cancer cells is probably due to the combined deregulation of genetic and epigenetic programs (23). In tumor cells, genes can be controlled by epigenetic modifications (24) and underlying genomic mutations that lead to reversible and irreversible changes, thereby resulting in activation of oncogenes and inactivation of tumor-suppressor genes (21,23,25-27). In other words, modifications in genetic information, such as double-strand breaks and fusions, can cause irreversible and stable changes in a cell (28), whereas epigenetic controls exert reversible and transient effects on cell behavior (23,29). Tumor development is a complex process driven by active (driver) and passive (passenger) mutations (30). The resultant tumors generally comprise heterogeneous tissues with tumor cell characteristics. It is generally considered that molecular mutations can lead to growth advantages during heterogeneous tumor formations, which ultimately increases tumor size. Furthermore, anti-apoptotic survival signals also support tumor development (31). The understanding of the involvement of changes in differentiation during tumor development remains somewhat elusive (23).

Recent studies indicate that aggressive tumors are associated with the preferential expression of ES-expressing genes, which suggests that common mechanisms are involved in the regulation of cancer stem cells (CSCs) and ES cells. Epigenetic regulating agents or events (including cell fusion and several epigenetic agents for DNA demethylation and histone acetylation) may reverse epigenetic information to normal biological characteristics in malignant tumors. A recent study that investigated the overexpression of the ES-expressing transcription factor indicated a modification in the epigenetic status and cancer cell behavior, after which the cells mimicked induced PSC (iPSC) behavior (32). Taken together, it is suggested that the viral-mediated transfection of transcription factors resulted in marked modification of epigenetic alterations in cancer cells due to its high magnitude of exogenous gene expression, whereas somewhat distinct alterations may develop in *de novo* cancer in terms of epigenetic net works, i.e., the activation of growth-promoting oncogenes and inactivation of tumor-suppressor genes. This suggests a possible experimental approach for using a reprogramming-like event in cancer research.

Cell reprogramming events observed in normal cells should be distinguished from reprogramming-like events

observed in cancer cells. i) Numerous studies have suggested that the genetic and epigenetic pathways in cancer cells differ from those in normal cells. Although some pathways may appear to be common, recent studies have indicated that only aggressive tumors are associated with the preferential expression of ES-expressing genes. ii) Cancer cells involve irreversible genetic changes that can be controlled by a one-way irreversible program; however, normal cells largely exert their differentiation program via reversible epigenetic modifications. For example, pancreatic PDX-1 was expressed transiently in pancreatic somatic stem or progenitor cells, whereas it was not expressed in differentiated endocrine or pancreatic cancer cells (33). iii) The introduction of four defined transcription factors, Oct4, Sox2, Klf4, and cMyc, resulted in complete reprogramming of mouse (18) and human fibroblasts (19). The introduction of the same four transcription factors into cancer cells induced the expression of genes related to an undifferentiated status and showed multipotentiality by differentiating into three germ layers, although they did not form a teratoma, a hallmark of pluripotency. This suggests that the induced pluripotency program may be partially altered by genetic mutations in cancer cells or that the cancer program initiated in normal multipotent cells may be different from the pluripotency program in normal cells.

4. Investigation of other factors

Reprogramming factors such as Oct3, Sox2, Klf4, and c-Myc were identified on the basis of their differential expression in fibroblasts and ES cells (18). However, like previous studies (34,35), future studies may elucidate the role of other new important factors in cellular reprogramming that may contribute considerably to the development of safe and effective clinical therapeutic options. Recent studies using an expression library of transcription factors expressed by unfertilized oocytes and fertilized one-cell zygotes have identified a novel maternal transcription factor, Gli-like transcription factor (Glisl; Glis family zinc finger 1). Glisl considerably enhances the generation of iPSCs from mouse and human fibroblasts, when it is expressed together with Oct4/Sox2/Klf4 (36). Glisl effectively promotes multiple reprogramming pathways, including Myc, Nanog, Lin28, Wnt, Essrb, and the EMT related-pathways, thereby indicating the usefulness of Glisl in effectively promoting the direct reprogramming of somatic cells during the generation of iPSC (36).

Small non-coding RNAs such as miRNAs, endogenous small interfering RNAs (endo-siRNAs), and Piwi-interacting RNAs (piRNAs) (37-39), have different but essential roles in mammalian development (40). Differences among the small non-coding RNA types can be determined using numerous properties, such as the size of endo-siRNAs (21 nucleotides, nt), which is distinct from that of piRNAs (31 nt). The sequence of an endosiRNA is completely complementary to its target transcripts, whereas that of an miRNA is usually only partially complementary to its target (37-39). Mature miRNAs are derived from precursor miRNAs that possess short stem-loop structures, whereas endo-siRNAs are processed from long dsRNAs without short stem-loop structures (37-39). It is

Table I. Summary of published studies concerning normal somatic cell reprogramming.

Method for factor delivery	Starting material	Efficiency	Reference
Retrovirus vector, OSKM	Mouse embryonic and adult fibroblasts	n.d.	(18)
Retrovirus vector, OSKM	Human fibroblasts	10 colonies/5x10 ⁴	(19)
Lentivirus, OSNL	Human fetal fibroblasts	198 colonies/0.9x10 ⁶	(73)
Plasmid transfection, OSKM	MEF	Lower than viral delivery method	(74)
Adenovirus (non-integrating vector), OSKM	MEF and hepatocytes	n.d.	(75)
Retrovirus, OSKM	Adult mouse liver and stomach cells	n.d.	(76)
Retrovirus, O(SKM)	Mouse neural stem cells	3.6-0.11%	(77)
Retrovirus, OSK(M)+VPA/5'Aza	MEF	0.5-11.8%, 100x higher than OSKM method	(78)
Dox-inducible lentiviruses, OSKM	Secondary somatic cells containing Dox-inducible OSKM expression (MEF, intestinal epithelium)	20-50x higher than direct infection method	(79)
Retrovirus, OSKM	Adult human adipose stem cells	0.2%	(80)
Repeated protein transduction, OSK(M)+VPA	MEF	Slower kinetics than viral delivery method	(81)
Retrovirus, OK+BIX/BayK compounds	Neural progenitor cells	12 colonies/3.5x10 ⁴	(82)
Doxycycline-inducible, OSKM transcription factors delivered by piggyBac transposition	Murine and human embryonic fibroblasts	n.d.	(83)
Retrovirus, OSK, miR-291-3p, miR-294 and miR-295	MEF	0.1-0.3%	(84)
Nucleofection, 2A-peptide linked cassette, OSKM	MEF	2.5%	(85)
Sendai virus, OSKM	Human terminally differentiated circulating T cells	0.1%	(86)
Lentivirus, Oct4 + compounds	Neonatal human epidermal keratinocytes, small human umbilical vein endothelial cell and amniotic fluid-derived cell	4-6 colonies/1x10 ⁶	(87)
Repeated transfection of synthetic modified mRNAs (OSKM)	Primary human neonatal epidermal keratinocytes, BJ human neonatal foreskin fibroblasts, human fetal lung fibroblasts and human fetal skin fibroblasts	1.4%, 36-fold higher than retrovirus	(88)
Lentivirus, miRNA 302s and 367, VPA	MEF, human fibroblasts	Faster kinetic efficiency, 2x higher than OSKM, efficiency 10000x higher	(46)
Repeated transfection & miR-302s, -369-3p, -369-5p, and -200c	Human and mouse adipose stromal cells, dermal fibroblasts	5 colonies/5x10 ⁴	(47)
Retrovirus, OSKM, miR-106b, -93, -106a and -17	MEF	Addition of miRNA enhanced efficiency 4- to 6-fold (miR-106b, 93) and 3 to 4-fold (miR-106a, 17)	(89)
Retrovirus, OSK(M), miR-302b, -372 and -294	Human fibroblasts	Addition of miRNA enhanced efficiency by promoting MET	(90)

O, Oct4; S, Sox2; K, Klf4; M, c-myc; L, Lin28; N, Nanog; n.d., not determined.

Table II. Summary of published studies concerning cancer cell reprogramming.

Method	Type of cancer	Characterization	Reference
Nuclear transfer	Medulloblastoma (Primary culture, mouse, Ptc1 heterozygous)	Cloned blastocyst can support postimplantation development, as the embryo appeared normal and showed extensive differentiation, although not viable after E8.5.	(91)
Nuclear transfer (2-step cloning)	Melanoma RAS ⁺ /Ink4a/Arf ^{-/-}	NT ES cells were able to form a teratoma and generate a chimera. Injection into tetraploid blastocyst resulted in normal embryo, viable until E9.5.	(92)
Nuclear transfer	Embryonal carcinoma	Nuclei from embryonal carcinoma can direct preimplantation development, resulting in normal blastocyst appearance. Higher efficiency when producing an ESC line compared to differentiated cells, although the degree of differentiation depended on the cell line character.	(93)
Embryonic micro-environment microRNA (miR 302a, b, c, and d)	Metastatic melanoma, breast cancer Melanoma (Colo), prostate	n.d.	(94)
Defined transcription factor (OKM)	Melanoma (R545)	Expression of pluripotency markers: Nanog, Oct4, Sox2, SSEA3, and SSEA4, demethylation of Oct4, cancer cell line (PC3) teratoma (+)	(48)
Defined transcription factor (OSKM)	Gastrointestinal cancer (colon, liver, pancreatic) DLD-1 completely characterized	Teratoma (+), chimera (+), expression of ESC marker, demethylation of Nanog and Oct4	(95)
Defined transcription factor (OSKM)	KBM7 cells derived from blast crisis stage chronic myeloid leukemia	Expression of pluripotency marker, demethylation of Nanog, <i>in vitro</i> differentiation into adipocyte, epithelial, mesenchymal, and neural lineage, teratoma (-)	(32)
Defined transcription factor (OSKM)	KBM7 cells derived from blast crisis stage chronic myeloid leukemia	Expression of ESC marker (+), demethylation of Oct4 and nanog, teratoma (+)	(96)
Defined transcription factor (OSLN)	A549 lung cancer	Demethylation of Oct4 promoter, expressed endogenous Nanog and Oct4 although lower than HESC, ALP (+), teratoma (-) Reprogramming efficiency was higher than that of normal primary lung fibroblast	(97)
Oocyte extract	Breast cancer (cell line, MCF7, HCC1945)	n.d.	(98)

O, Oct4; S, Sox2; K, Klf4; M, c-myc; L, Lin28; N, Nanog; n.d., not determined.

generally accepted that piRNAs are expressed during male gametogenesis where they play a crucial role, whereas endo-siRNAs are essential during oocyte meiosis (37-40). In

contrast, miRNAs are ubiquitously expressed in somatic tissues and function throughout postimplantation development (37-40).

Recent studies indicate that small non-coding RNAs undergo a complex, but finely tuned regulation in the early stages of cell reprogramming, i.e., during transition from a differentiated oocyte to a pluripotent blastomere. piRNAs and endo-siRNAs correspond to mRNAs or retrotransposons in growing oocytes (41). In oocytes, piRNAs are bound to Mili and regulate retrotransposons, while siRNAs are exclusively mapped to retrotransposons or other genomic regions that form dsRNA structures (41). The components of the piRNA pathway are also required for *de novo* methylation of the differentially methylated region (DMR) of the imprinted mouse *Rasgrf1* locus, but not other paternally imprinted loci. A retrotransposon sequence within a non-coding RNA region that spans DMR was targeted by piRNAs generated from a different locus (42). Male germ cells express abundant endogenous siRNAs that can potentially target hundreds of transcripts and/or thousands of DNA regions in the genome, including retrotransposon sequences. This suggests the possibility of complex uncharacterized regulation imposed by small non-coding RNAs during male germ cell development (43). Interestingly, miRNAs were shown to be non-essential during preimplantation embryonic development and their function was suppressed during oocyte meiosis. Furthermore, endo-siRNAs, rather than miRNAs, play a role during oocyte maturation and preimplantation development (40,44,45). The introduction of miRNAs is sufficient to induce a pluripotent phenotype in differentiated somatic cells (46,47) without the addition of transcription factors. miRNA-induced reprogramming is probably related to the alteration of aggressive cancer phenotypes (32,48,49). Thus, these studies suggest that a fraction of endogenous siRNAs are involved in oocyte reprogramming. Future studies are required to search for endogenous siRNAs in meiotic oocytes, mitotic zygotes, and early embryos. A detailed understanding of these processes may lead to small non-coding RNAs proving beneficial in altering cancerous phenotypes.

Retrotransposon-type repetitive sequences are involved in cancer chromosome translocation. These repetitive sequences are characteristic genomic sequences in fragile sites commonly found in various chromosomes, including *FRA3B* and *FRA16D* (50-54). Rare fragile sites are often associated with particular sequences (55). Fragile sites often coincide with genes that are frequently rearranged or deleted in human cancers. More than half of cancer-specific translocations contain breakpoints within fragile sites (56,57). Replication stress is usually caused by carcinogen exposure or other cancer-induction events, and the ataxia-telangiectasia-related (Atr) DNA damage checkpoint pathway plays a crucial role in maintaining genomic stability at fragile chromosome sites (58). Recent findings have confirmed that Atr protein binds to three regions of *FRA3B* during mild replication stress (57). During dysplasia, loss of Fhit expression leads to a direct and significant influence on changes in checkpoint proteins, suggesting a connection between Fhit loss and modulation of checkpoint activity (57,59). In cancer, changes in miRNA expression are frequently associated with changes at fragile chromosome sites (60). Interestingly, the DNA damage-susceptible *FRA3B/FHIT* chromosome fragile site encodes a protein required for protecting cells from accumulated DNA damage through its ability to modulate the checkpoint proteins Atr and Chk1, whereas inactivation of Fhit contributes to the accumulation of

abnormal checkpoint phenotypes during cancer development (61-63). The absence of Fhit protein in stem cells, a reduction in oxidative stress, and efficient but not error-free DNA damage repair, facilitate the unscheduled long-term survival of genotoxin-exposed Fhit-deficient hematopoietic stem cells that carry deleterious mutations (64). Thus, the small noncoding RNAs are nucleotides that can affect cancer risk. The catalog of known miRNAs and a large fraction of genomic ultraconserved regions (UCRs) that encode a particular set of non-coding RNAs located at fragile sites and/or cancer susceptibility loci, the expression of which is altered in human cancers, was recently updated (65). These types of studies are the first step toward discovering novel approaches for cancer therapies (65). The next logical research step would be to study the relationship between UCRs, the stemness-regulating region of CSCs, and the therapeutic control of CSCs and EMT (66,67). The regulation of cancer phenotypes by small noncoding RNAs has emerged as an important component of pharmacogenomics, and one day it may be used as an efficient therapeutic approach for cancer (68-70).

5. Perspectives

The regulatory mechanism of cell differentiation in cancer is unclear, and it is debatable whether cancer cells can actually be reprogrammed. The cell of origin for cancer remains unknown, and hence, the underlying mechanism controlling initial programming during cancer remains elusive (32,48,71,72). Epigenetic modifications are involved in the aggressive behavior of cancer cells; therefore, utilizing these modifications for therapeutic purposes may be challenging.

References

1. Ambros V: The functions of animal microRNAs. *Nature* 431: 350-355, 2004.
2. John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. *PLoS Biol* 2: e363, 2004.
3. Houbaviy HB, Murray MF and Sharp PA: Embryonic stem cell-specific microRNAs. *Dev Cell* 5: 351-358, 2003.
4. Lim LP, Glasner ME, Yekta S, Burge CB and Bartel DP: Vertebrate microRNA genes. *Science* 299: 1540, 2003.
5. Leung AK and Sharp PA: MicroRNA functions in stress responses. *Mol Cell* 40: 205-215, 2010.
6. Marsit CJ, Eddy K and Kelsey KT: MicroRNA responses to cellular stress. *Cancer Res* 66: 10843-10848, 2006.
7. Ng HH and Surani MA: The transcriptional and signalling networks of pluripotency. *Nat Cell Biol* 13: 490-496, 2011.
8. Calin GA, Dumitru CD, Shimizu M, *et al*: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 99: 15524-15529, 2002.
9. Calin GA, Ferracin M, Cimmino A, *et al*: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *N Engl J Med* 353: 1793-1801, 2005.
10. Cerchia L and De Francis V: Noncoding RNAs in cancer medicine. *J Biomed Biotechnol* 2006: 1-8, 2006.
11. Cummins JM, He Y, Leary RJ, *et al*: The colorectal microRNAome. *Proc Natl Acad Sci USA* 103: 3687-3692, 2006.
12. Wijnhoven B, Michael MZ and Watson DI: MicroRNAs and cancer. *Br J Surg* 94: 23-30, 2007.
13. Davis RL, Weintraub H and Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 51: 987-1000, 1987.
14. Xie H, Ye M, Feng R and Graf T: Stepwise reprogramming of B cells into macrophages. *Cell* 117: 663-676, 2004.
15. Zhou Q, Brown J, Kanarek A, Rajagopal J and Melton DA: In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. *Nature* 455: 627-632, 2008.

16. French SW, Hoyer KK, Shen RR and Teitell MA: Transdifferentiation and nuclear reprogramming in hematopoietic development and neoplasia. *Immunol Rev* 187: 22-39, 2002.
17. Ungefroren H and Fändrich F: The programmable cell of monocytic origin (PCMO): a potential adult stem/progenitor cell source for the generation of islet cells. *Adv Exp Med Biol* 654: 667-682, 2010.
18. Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126: 663-676, 2006.
19. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131: 861-872, 2007.
20. Yamanaka S: Elite and stochastic models for induced pluripotent stem cell generation. *Nature* 460: 49-52, 2009.
21. Hanahan D and Weinberg RA: The hallmarks of cancer. *Cell* 100: 57-70, 2000.
22. McKenna ES and Roberts CW: Epigenetics and cancer without genomic instability. *Cell Cycle* 8: 23-26, 2009.
23. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. *Cell* 144: 646-674, 2011.
24. Rodríguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. *Nat Med* 17: 330-339, 2011.
25. Cavenee W, Dryja TP, Phillips RA, *et al*: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature* 305: 779-784, 1983.
26. Weinberg R: Tumor suppressor genes. *Science* 254: 1138-1146, 1991.
27. Weinberg RA: The retinoblastoma protein and cell cycle control. *Cell* 81: 323-330, 1995.
28. Wang JY: Cellular responses to DNA damage. *Curr Opin Cell Biol* 10: 240-247, 1998.
29. Solinas G, Marchesi F, Garlanda C, Mantovani A and Allavena P: Inflammation-mediated promotion of invasion and metastasis. *Cancer Metastasis Rev* 29: 243-248, 2010.
30. Vogelstein B and Kinzler KW: The multistep nature of cancer. *Trends Genet* 9: 138-141, 1993.
31. Bonavia R, Inda MD, Cavenee WK and Furnari FB: Heterogeneity maintenance in glioblastoma: a social network. *Cancer Res* 71: 4055-4060, 2011.
32. Miyoshi N, Ishii H, Nagai K, *et al*: Defined factors induce reprogramming of gastrointestinal cancer cells. *Proc Natl Acad Sci USA* 107: 40-45, 2010.
33. Friedlander SYG, Chu GC, Snyder EL, *et al*: Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. *Cancer Cell* 16: 379-389, 2009.
34. Orkin SH and Hochedlinger K: Chromatin connections to pluripotency and cellular reprogramming. *Cell* 145: 835-850, 2011.
35. Gurdon JB and Wilmut I: Nuclear transfer to eggs and oocytes. *Cold Spring Harb Perspect Biol* 3: 1-14, 2011.
36. Maekawa M, Yamaguchi K, Nakamura T, *et al*: Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. *Nature* 474: 225-229, 2011.
37. Nilsen TW: Endo-siRNAs: Yet another layer of complexity in RNA silencing. *Nat Struct Mol Biol* 15: 546-548, 2008.
38. Golden DE, Gerbasi VR and Sontheimer EJ: An inside job for siRNAs. *Mol Cell* 31: 309-312, 2008.
39. Okamura K and Lai EC: Endogenous small interfering RNAs in animals. *Nat Rev Mol Cell Biol* 9: 673-678, 2008.
40. Suh N and Blelloch R: Small RNAs in early mammalian development: from gametes to gastrulation. *Development* 138: 1653-1661, 2011.
41. Watanabe T, Totoki Y, Toyoda A, *et al*: Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. *Nature* 453: 539-543, 2008.
42. Watanabe T, Tomizawa S, Mitsuya K, *et al*: Role for piRNAs and noncoding RNA in de novo DNA methylation of the imprinted mouse Rasgrf1 locus. *Science* 332: 848-852, 2011.
43. Song R, Hennig GW, Wu Q, Jose C, Zheng H and Yan W: Male germ cells express abundant endogenous siRNAs. *Proc Natl Acad Sci USA* 108: 13159-13164, 2011.
44. Suh N, Baehner L, Moltzahn F, Melton C, Shenoy A, Chen J and Blelloch R: MicroRNA function is globally suppressed in mouse oocytes and early embryos. *Curr Biol* 20: 271-277, 2010.
45. Ma J, Flemr M, Stein P, *et al*: MicroRNA activity is suppressed in mouse oocytes. *Curr Biol* 20: 265-270, 2010.
46. Anokye-Danso F, Trivedi CM, Juhr D, *et al*: Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell* 8: 376-388, 2011.
47. Miyoshi N, Ishii H, Nagano H, *et al*: Reprogramming of mouse and human cells to pluripotency using mature microRNAs. *Cell Stem Cell* 8: 633-638, 2011.
48. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT and Ying SY: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. *RNA* 14: 2115-2124, 2008.
49. Lin SL, Chang DC, Ying SY, Leu D and Wu DT: MicroRNA miR-302 inhibits the tumorigenicity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. *Cancer Res* 70: 9473-9482, 2010.
50. Sozzi G, Huebner K and Croce CM: FHIT in human cancer. *Adv Cancer Res* 74: 141-166, 1998.
51. Huebner K and Croce CM: FRA3B and other common fragile sites: the weakest link. *Nat Rev Cancer* 1: 214-221, 2001.
52. Arlt MF, Casper AM and Glover TW: Common fragile sites. *Cytogenet Genome Res* 100: 92-100, 2003.
53. Cimprich KA: Fragile sites: breaking up over a slowdown. *Curr Biol* 13: R231-R233, 2003.
54. Durkin SG and Glover TW: Chromosome fragile sites. *Annu Rev Genet* 41: 169-192, 2007.
55. Sutherland GR: Rare fragile sites. *Cytogenet Genome Res* 100: 77-84, 2003.
56. Croce CM, Sozzi G and Huebner K: Role of FHIT in human cancer. *J Clin Oncol* 17: 1618-1624, 1999.
57. Dillon LW, Burrow AA and Wang YH: DNA instability at chromosomal fragile sites in cancer. *Curr Genomics* 11: 326-337, 2010.
58. Casper AM, Nghiem P, Arlt MF and Glover TW: ATR regulates fragile site stability. *Cell* 111: 779-789, 2002.
59. Cirombella R, Montrone G, Stoppacciaro A, *et al*: Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. *Cancer Lett* 291: 230-236, 2010.
60. Calin GA, Sevignani C, Dumitru CD, *et al*: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci USA* 101: 2999-3004, 2004.
61. Hu B, Wang H, Wang X, *et al*: Fhit and CHK1 have opposing effects on homologous recombination repair. *Cancer Res* 65: 8613-8616, 2005.
62. Ishii H, Mimori K, Inoue H, *et al*: Fhit modulates the DNA damage checkpoint response. *Cancer Res* 66: 11287-11292, 2006.
63. Okumura H, Ishii H, Pichiorri F, Croce CM, Mori M and Huebner K: Fragile gene product, Fhit, in oxidative and replicative stress responses. *Cancer Sci* 100: 1145-1150, 2009.
64. Ishii H, Mimori K, Ishikawa K, *et al*: Fhit-deficient hematopoietic stem cells survive hydroquinone treatment long-term, carrying precancerous alterations. *Cancer Res* 68: 3662-3670, 2008.
65. Rossi S, Sevignani C, Nnadi SC, Siracusa LD and Calin GA: Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. *Mamm Genome* 19: 526-540, 2008.
66. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S and Sarkar FH: Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. *Drug Resist Updat* 13: 109-118, 2010.
67. Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. *Cancer Lett* 300: 10-19, 2011.
68. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, and Calin GA: microRNAs in cancer: from bench to bedside. *Adv Cancer Res* 108: 113-157, 2010.
69. Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. *Nat Rev Drug Discov* 9: 775-789, 2010.
70. White NM, Fatoohi E, Metias M, Jung K, Stephan C and Yousef GM: Metastamirs: a stepping stone towards improved cancer management. *Nat Rev Clin Oncol* 8: 75-84, 2011.
71. Kasemeier-Kulesa JC, Teddy JM, Postovit LM, Seftor EA, Seftor RE, Hendrix MJ and Kulesa PM: Reprogramming multipotent tumor cells with the embryonic neural crest micro-environment. *Dev Dyn* 237: 2657-2666, 2008.
72. Wang J, Emadali A, Le Bescont A, Callanan M, Rousseaux S and Khochbin S: Induced malignant genome reprogramming in somatic cells by testis-specific factors. *Biochim Biophys Acta* 1809: 221-225, 2011.
73. Yu J, Vodyanik MA, Smuga-Otto K, *et al*: Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318: 1917-1920, 2007.
74. Okita K, Nakagawa M, Hyenjong H, Ichisaka T and Yamanaka S: Generation of mouse induced pluripotent stem cells without viral vectors. *Science* 322: 949-953, 2008.

75. Stadtfeld M, Nagaya M, Utikal J, Weir G and Hochedlinger K: Induced pluripotent stem cells generated without viral integration. *Science* 322: 945-949, 2008.
76. Aoi T, Yae K, Nakagawa M, *et al*: Generation of pluripotent stem cells from adult mouse liver and stomach cells. *Science* 321: 699-702, 2008.
77. Kim JB, Zaehres H, Wu G, Gentile L, *et al*: Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. *Nature* 454: 646-650, 2008.
78. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE and Melton DA: Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol* 26: 795-797, 2008.
79. Wernig M, Lengner CJ, Hanna J, *et al*: A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. *Nat Biotechnol* 26: 916-924, 2008.
80. Sun N, Panetta NJ, Gupta DM, *et al*: Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. *Proc Natl Acad Sci USA* 106: 15720-15725, 2009.
81. Zhou H, Wu S, Joo JY, *et al*: Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 4: 381-384, 2009.
82. Shi Y, Do JT, Despons C, Hahm HS, Schöler HR and Ding S: A combined chemical and genetic approach for the generation of induced pluripotent stem cells. *Cell Stem Cell* 2: 525-528, 2008.
83. Woltjen K, Michael IP, Mohseni P, *et al*: piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 458: 766-770, 2009.
84. Judson RL, Babiarz JE, Venere M and Blum R: Embryonic stem cell-specific microRNAs promote induced pluripotency. *Nat Biotechnol* 27: 459-461, 2009.
85. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P and Woltjen K: Virus-free induction of pluripotency and subsequent excision of reprogramming factors. *Nature* 458: 771-775, 2009.
86. Seki T, Yuasa S, Oda M, *et al*: Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. *Cell Stem Cell* 7: 11-14, 2010.
87. Warren L, Manos PD, Ahfeldt T, *et al*: Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* 7: 618-630, 2010.
88. Zhu S, Li W, Zhou H, *et al*: Reprogramming of human primary somatic cells by OCT4 and chemical compounds. *Cell Stem Cell* 7: 651-655, 2010.
89. Li Z, Yang CS, Nakashima K and Rana TM: Small RNA-mediated regulation of iPS cell generation. *EMBO J* 30: 823-834, 2011.
90. Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R and Blum R: Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. *Nat Biotechnol* 29: 443-448, 2011.
91. Li L, Connelly MC, Wetmore C, Curran T and Morgan JJ: Mouse embryos cloned from brain tumors. *Cancer Res* 63: 2733-2736, 2003.
92. Hochedlinger K, Blum R, Brennan C, Yamada Y, Kim M, Chin L and Jaenisch R: Reprogramming of a melanoma genome by nuclear transplantation. *Genes Dev* 18: 1875-1885, 2004.
93. Blum RH, Hochedlinger K, Yamada Y, *et al*: Nuclear cloning of embryonal carcinoma cells. *Proc Natl Acad Sci USA* 101: 13985-13990, 2004.
94. Postovit LM, Margaryan NV, Seftor EA, *et al*: Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. *Proc Natl Acad Sci USA* 105: 4329-4334, 2008.
95. Utikal J, Maherali N, Kulal W and Hochedlinger K: Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. *J Cell Sci* 122: 3502-3510, 2009.
96. Carrette JE, Pruszk J, Varadarajan M, Blumen VA and Gokhale S: Generation of iPSCs from cultured human malignant cells. *Blood* 115: 4039-4042, 2010.
97. Mathieu J, Zhang Z, Zhou W, Wang AJ and Heddleston JM: HIF induces human embryonic stem cell markers in cancer cells. *Cancer Res* 71: 4640-4652, 2011.
98. Allegrucci C, Rushton MD, Dixon JE, *et al*: Epigenetic reprogramming of breast cancer cells with oocyte extracts. *Mol Cancer* 10: 7, 2011.